Evidence map›Paper›PMID 27096954›Full record

ArticleOncotarget2016

Optical and nuclear imaging of glioblastoma with phosphatidylserine-targeted nanovesicles.

Víctor M Blanco, Zhengtao Chu, Kathleen LaSance, Brian D Gray, Koon Yan Pak, Therese Rider, Kenneth D Greis, Xiaoyang Qi

Abstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Medical Imaging Technology and Imaging Agents.Advances in experimental medicine and biology · 2023
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Targeting VPAC1 Receptors for Imaging Glioblastoma.Molecular imaging and biology · 2020
    Article
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Víctor M BlancoDivision of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA.
Zhengtao ChuDivision of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA.
Kathleen LaSanceDepartment of Radiology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA.
Brian D GrayMolecular Targeting Technologies, Inc., West Chester, Pennsylvania 19380, USA.
Koon Yan PakMolecular Targeting Technologies, Inc., West Chester, Pennsylvania 19380, USA.
Therese RiderDepartment of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA.
Kenneth D GreisDepartment of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA.
Xiaoyang QiDivision of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA.

Funding

Acidic Phospholipid-Selective Treatment for NeuroblastomaR01CA158372 · NCI · UNIVERSITY OF CINCINNATI · PI QI, XIAOYANG · 2011 to 2015
$1.6M
Intravenous Enzyme Replacement Therapy for CNS DisordersR21NS095047 · NINDS · UNIVERSITY OF CINCINNATI · PI QI, XIAOYANG · 2015 to 2016
$447k
NCI NIH HHS R01 CA158372NINDS NIH HHS R21 NS095047
6 · The paper itself

Abstract

Multimodal tumor imaging with targeted nanoparticles potentially offers both enhanced specificity and sensitivity, leading to more precise cancer diagnosis and monitoring. We describe the synthesis and characterization of phenol-substituted, lipophilic orange and far-red fluorescent dyes and a simple radioiodination procedure to generate a dual (optical and nuclear) imaging probe. MALDI-ToF analyses revealed high iodination efficiency of the lipophilic reporters, achieved by electrophilic aromatic substitution using the chloramide 1,3,4,6-tetrachloro-3α,6α-diphenyl glycoluril (Iodogen) as the oxidizing agent in an organic/aqueous co-solvent mixture. Upon conjugation of iodine-127 or iodine-124-labeled reporters to tumor-targeting SapC-DOPS nanovesicles, optical (fluorescent) and PET imaging was performed in mice bearing intracranial glioblastomas. In addition, tumor vs non-tumor (normal brain) uptake was compared using iodine-125. These data provide proof-of-principle for the potential value of SapC-DOPS for multimodal imaging of glioblastoma, the most aggressive primary brain tumor.

Indexed as

Positron-Emission TomographyAnimalsBrain NeoplasmsCell Line, TumorCell ProliferationFemaleFluorescent DyesGlioblastomaHeterograftsHumansLuminescent MeasurementsMice, NudeMultimodal ImagingNanoparticlesOptical ImagingPhosphatidylserines1,2-dioleoylphosphatidylserineFluorescent DyesPhosphatidylserinesRadiopharmaceuticalsSaposinsglioblastomaliposomeoptical imagingPETSapC-DOPS

Identifiers

PMID27096954
PMCPMC5078058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.